Search filters

List of works by John Lunec

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

scientific article published on 16 March 2018

A multilocus technique for risk evaluation of patients with neuroblastoma

scientific article published on February 2011

ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma

scientific article published on 20 December 2018

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group

scientific article published on 09 September 2020

Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain

scientific article published on December 1, 1992

COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib

scientific article

Cell cycle regulation targets of MYCN identified by gene expression microarrays

scientific article published on May 2007

Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours

scientific article published on 31 January 2018

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor

scientific article published on 14 August 2018

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

scientific article published on 15 July 2017

DNA repair and repair fidelity in metastatic variants of the B16 murine melanoma ⬇️

scientific article published on 01 March 1993

Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.

scientific article published on August 2003

Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and in

scientific article

Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line

scientific article

Functional characterisation of a novel ovarian cancer cell line, NUOC-1.

scientific article

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

scientific article

High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays

scientific article published on January 2007

Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 Inhibition

scientific article published on 12 June 2018

Histological profile of tumours from MYCN transgenic mice

scientific article

Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation ⬇️

scientific article published on August 17, 2012

Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse

scientific article published on February 2006

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

scientific article published on 4 November 2014

Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency

scientific article published on 11 February 2011

Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.

scientific article published on March 2005

MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.

scientific article

MSH receptor expression and the relationship to melanogenesis and metastatic activity in B16 melanoma

scientific article published on 01 May 1992

MYCN oncoprotein targets and their therapeutic potential

scientific article published on 13 February 2010

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

scientific article published on 04 July 2011

Mitotic percentage index: a new prognostic factor for childhood medulloblastoma ⬇️

scientific article published on April 1, 1997

Murine melanoma cell differentiation and melanogenesis induced by poly(ADP-ribose) polymerase inhibitors

scientific article published on October 1, 1992

No Evidence for Correlation of DDX1 Gene Amplification With Improved Survival Probability in Patients With MYCN-Amplified Neuroblastomas

article

Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells

scientific article published on 19 April 2019

Non-glucose metabolism in cancer cells—is it all in the fat? ⬇️

scientific article published on December 1, 2012

Of dogs and men: Comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma ⬇️

scientific article published on October 11, 2011

Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.

scientific article

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.

scientific article published on 2 November 2015

Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors

scientific article published on 22 February 2016

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.

scientific article published on 20 May 2016

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma

scientific article

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

scientific article published on 09 January 2019

Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder ⬇️

scientific article published on 01 November 2001

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

scientific article published on 22 May 2018

Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay

scientific article published in February 2002

Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach

scientific article

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold

scientific article published in October 2006

Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma

scientific article

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation

scientific article published on 15 June 2016

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers

scientific article published on 23 October 2020

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma

scientific article

The expression of functional MSH receptors on cultured human melanocytes

scientific article published on 01 January 1992

The neuroblastoma amplified gene, NAG : genomic structure and characterisation of the 7.3 kb transcript predominantly expressed in neuroblastoma ⬇️

scientific article published on March 27, 2003

The p53 pathway and its inactivation in neuroblastoma.

scientific article

The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQTM in human leukaemia and colorectal carcinoma cell lines ⬇️

scientific article published on January 1, 1997

The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage

scientific article published on 15 November 2006

Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53WT Uterine Leiomyosarcoma

scientific article published in 2021

mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response

scientific article published on 07 March 2019

p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells

scientific article published on June 2001

p53 is a direct transcriptional target of MYCN in neuroblastoma

scientific article published on 09 February 2010

p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma

scientific article

Paulina is supported by:

About Paulina

Help